The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Improving care with portfolio of physician-led cancer quality measures at an academic center.
 
Julie Porter
No Relationships to Disclose
 
Andrea Segura Smith
No Relationships to Disclose
 
Marcy Winget
No Relationships to Disclose
 
Eben Lloyd Rosenthal
Consulting or Advisory Role - Aspirion Health Resources; Medrobotics; Novadaq Technologies; SurgVision
Research Funding - LI-COR Biosciences (Inst); Novadaq Technologies (Inst)
 
Sridhar Belavadi Seshadri
No Relationships to Disclose
 
Yohan Vetteth
No Relationships to Disclose
 
Eileen F Kiamanesh
No Relationships to Disclose
 
Amogh Badwe
No Relationships to Disclose
 
Ranjana H. Advani
Honoraria - GE Healthcare
Consulting or Advisory Role - Forty Seven; Genentech/Roche; Kyowa Hakko Kirin
Research Funding - Agensys (Inst); Allos Therapeutics (Inst); Celgene (Inst); Genentech/Roche (Inst); Idera (Inst); Infinity Pharmaceuticals; Janssen (Inst); Kura Oncology; Merck; Millennium (Inst); Pharmacyclics (Inst); Regeneron; Seagen (Inst)
Travel, Accommodations, Expenses - Kyowa Hakko Kirin; Seagen
 
Mark K. Buyyounouski
No Relationships to Disclose
 
Steven Coutre
Stock and Other Ownership Interests - Pharmacyclics (I)
Honoraria - Gilead Sciences
Consulting or Advisory Role - Abbvie; Celgene; Genentech/Roche; Gilead Sciences; Janssen Oncology; Novartis; Pharmacyclics
Research Funding - Abbvie (Inst); Celgene (Inst); Gilead Sciences (Inst); Novartis (Inst); Pharmacyclics (Inst)
Travel, Accommodations, Expenses - abbvie; Celgene; Gilead Sciences; Janssen Oncology; Novartis; Pharmacyclics
 
Oliver Dorigo
No Relationships to Disclose
 
Kristen N. Ganjoo
No Relationships to Disclose
 
Laura J. Johnston
No Relationships to Disclose
 
Lawrence David Recht
No Relationships to Disclose
 
Joseph B Shrager
No Relationships to Disclose
 
Eila C. Skinner
No Relationships to Disclose
 
Susan M. Swetter
No Relationships to Disclose
 
Brendan C. Visser
No Relationships to Disclose
 
Douglas W. Blayney
Stock and Other Ownership Interests - Abbott Laboratories; Amgen; Bristol-Myers Squibb; Citrix Systems; Clinical Oncology Advisory Group; Covidien; Express Scripts; Google; IBM; Johnson & Johnson; Oracle Corporation; PRM Pharmaceutical; United Health Group
Consulting or Advisory Role - Apotex; AstraZeneca/MedImmune; AVEO; Bristol-Myers Squibb; Cephalon; Clinical Oncology Advisory Group; Genentech/Roche; GlaxoSmithKline; Pfizer; Physician Resource Management; PRM Pharmaceutical; Prometheus; SOBI; Taiho Pharmaceutical; Teva; UnitedHealthcare
Research Funding - Amgen (Inst)